stedi glp 1 reviews and complaints Genuinely don’t know what I’m meant to do to stop my name being used to ‘endorse’ shonky products. This clearly isn’t endorsed by me. The Guardian wrote an article about this problem, the rise in STDEI GLP-1 Oral Solution Review:

Regular monitoring and follow-up consultations are essential to ensure safety and efficacy, allowing for timely adjustments to the treatment plan as needed

Combining incretin-based drugs and RAAS inhibitors: more cons than pros

They often occur when initiating treatment or during dose escalation and subside over time as the body adjusts to the medication

International note Retatrutide is also not approved in the UK, EU, Australia, Canada, or any other major market as of June 2026

However, individuals with a BMI of 27 or above who also have weight-related medical conditions, such as hypertension, type 2 diabetes, or dyslipidemia, may also be eligible